All-oral regimens will likely take the bulk of the market in the first-line setting.
I suspect we place different odds on this -g-. I'd give 50% odds that IFN is still used in >50% of G1 patients in 2015 (for relapse reasons)
Pegasys biosimilars will enter the market in due course.
How much market share do generics normally capture when there is a substantially improved (better efficacy and tollerability) name brand on the market - e.g. how much market share does pravastatin have?
Many patients will need only 24 weeks of ifn, but the fact that some patients will still need 48 weeks precludes a price hike to offset the shorter duration for 24-week patients.
Assuming that IFN-L does have substantially better efficacy and SAE then I would suggest that they will have pricing power.
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM